These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 16899610)

  • 41. What to do with IL-2?
    Dillman RO
    Cancer Biother Radiopharm; 1999 Dec; 14(6):423-34. PubMed ID: 10850329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.
    Choi SH; Byun HM; Kwan JM; Issa JP; Yang AS
    Br J Haematol; 2007 Sep; 138(5):616-23. PubMed ID: 17686055
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells.
    Gollob JA; Sciambi CJ
    Clin Cancer Res; 2007 Sep; 13(17):5219-25. PubMed ID: 17785578
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
    Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
    Lindsey KR; Rosenberg SA; Sherry RM
    J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
    Fang F; Balch C; Schilder J; Breen T; Zhang S; Shen C; Li L; Kulesavage C; Snyder AJ; Nephew KP; Matei DE
    Cancer; 2010 Sep; 116(17):4043-53. PubMed ID: 20564122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decitabine, independent of apoptosis, exerts its cytotoxic effects on cell growth in melanoma cells.
    Liu QY; Chen DW; Xie LP; Zhang RQ; Wang HZ
    Environ Toxicol Pharmacol; 2011 Nov; 32(3):423-9. PubMed ID: 22004962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma.
    Koulova L; Novik Y; Caliendo G; Wiernik P; Dutcher J
    J Immunother; 2005; 28(6):576-81. PubMed ID: 16224275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2.
    Citterio G; Pellegatta F; Lucca GD; Fragasso G; Scaglietti U; Pini D; Fortis C; Tresoldi M; Rugarli C
    Br J Cancer; 1996 Oct; 74(8):1297-301. PubMed ID: 8883421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
    Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
    J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
    Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
    Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
    Stewart DJ; Issa JP; Kurzrock R; Nunez MI; Jelinek J; Hong D; Oki Y; Guo Z; Gupta S; Wistuba II
    Clin Cancer Res; 2009 Jun; 15(11):3881-8. PubMed ID: 19470736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
    Chu BF; Karpenko MJ; Liu Z; Aimiuwu J; Villalona-Calero MA; Chan KK; Grever MR; Otterson GA
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):115-21. PubMed ID: 23053268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
    Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
    J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decitabine for acute myeloid leukemia.
    Marks PW
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):299-305. PubMed ID: 22369322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
    Issa JP; Garcia-Manero G; Giles FJ; Mannari R; Thomas D; Faderl S; Bayar E; Lyons J; Rosenfeld CS; Cortes J; Kantarjian HM
    Blood; 2004 Mar; 103(5):1635-40. PubMed ID: 14604977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
    Scandura JM; Roboz GJ; Moh M; Morawa E; Brenet F; Bose JR; Villegas L; Gergis US; Mayer SA; Ippoliti CM; Curcio TJ; Ritchie EK; Feldman EJ
    Blood; 2011 Aug; 118(6):1472-80. PubMed ID: 21613261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
    Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies.
    Lindemann A; Hoeffken K; Schmidt RE; Diehl V; Kloke O; Gamm H; Hayungs J; Oster W; Boehm M; Franks CR
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():53-7. PubMed ID: 2670215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
    Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
    PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.